scholarly journals NTCT-13VAGOGLOSSOPHARYNGEAL NEURALGIA PRESENTING AS FREQUENT SEIZURE-LIKE SPELLS IN A PATIENT WITH HEAD AND NECK CANCER TREATED WITH HIGH CUMULATIVE RADIATION DOSE

2015 ◽  
Vol 17 (suppl 5) ◽  
pp. v174.5-v175
Author(s):  
Alicia Zukas ◽  
David Schiff
2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 6040-6040
Author(s):  
Anna C. H. Willemsen ◽  
Annemieke Kok ◽  
Laura W.J. Baijens ◽  
J. P. De Boer ◽  
Remco de Bree ◽  
...  

6040 Background: Patients who receive chemoradiation or bioradiation (CRT/BRT) for locally advanced head and neck squamous cell carcinoma (LAHNSCC) often experience high toxicity rates, which may interfere with oral intake, leading to (temporary) tube feeding (TF) dependency. International guidelines recommend gastrostomy insertion when the expected use of TF exceeds four weeks. In this study we aimed to update and externally validate a prediction model to identify patients in need for TF for at least four weeks, meeting the international criteria for prophylactic gastrostomy insertion. Methods: This retrospective multicenter cohort study was performed in four tertiary referral head and neck cancer centers in the Netherlands. The prediction model was developed using data from the University Medical Center Utrecht and the Netherlands Cancer Institute. The model was externally validated in patients from the Maastricht University Medical Center and Radboud University Medical Center. The primary endpoint was TF, initiated during or within 30 days after completion of CRT/BRT, and administered for at least four weeks. Potential predictors were retrieved from patient medical records and radiotherapy dose-volume parameters were calculated. Results: The developmental and validation cohort included 409 and 334 patients respectively. Multivariable analysis showed significant predictive value (p < 0.05) for adjusted diet at start of CRT/BRT, percentage weight change prior to treatment initiation, WHO performance status, tumor-site, nodal stage, mean radiation dose to the contralateral parotid gland, and mean radiation dose to the oral cavity. The area under the receiver operating characteristics curve for the updated model was 0.73 and after external validation 0.64. Positive and negative predictive value at 90% cut off were 80.0% and 48.2% respectively. Conclusions: This externally validated prediction model to estimate TF-dependency for at least four weeks in LAHNSCC patients performs well. This model, which will be presented, can be used in clinical practice to guide personalized decision making on prophylactic gastrostomy insertion.


2020 ◽  
Vol 59 (5) ◽  
pp. 525-533 ◽  
Author(s):  
Katrin Håkansson ◽  
Bob Smulders ◽  
Lena Specht ◽  
Mingyao Zhu ◽  
Jeppe Friborg ◽  
...  

Medicine ◽  
2017 ◽  
Vol 96 (26) ◽  
pp. e7186 ◽  
Author(s):  
Shih-Neng Yang ◽  
Yu-Rou Chiou ◽  
Geoffrey G. Zhang ◽  
Kuei-Ting Chou ◽  
Tzung-Chi Huang

2014 ◽  
Vol 41 (6Part29) ◽  
pp. 505-506
Author(s):  
H Gay ◽  
J Oh ◽  
A Apte ◽  
P Dyk ◽  
D Mullen ◽  
...  

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 5546-5546 ◽  
Author(s):  
D. Gustin ◽  
D. J. Haraf ◽  
K. Stenson ◽  
E. Cohen ◽  
F. Rosen ◽  
...  

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 5546-5546
Author(s):  
D. Gustin ◽  
D. J. Haraf ◽  
K. Stenson ◽  
E. Cohen ◽  
F. Rosen ◽  
...  

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22134-e22134
Author(s):  
S. Bhide ◽  
S. Gulliford ◽  
R. A'Hern ◽  
E. Hall ◽  
K. Newbold ◽  
...  

e22134 Purpose: To generate quantitative parameters describing the effect of concomitant chemotherapy on incidence of grade 3 dysphagia (CTCAE v3.0, assisted feeding) using dose response curves in patients receiving radical treatment for head and neck cancer. Methods: Patients treated at a single centre in prospective phase I and II trials of concomitant chemo-IMRT (CRT) (n=85) and the phase III trial of IMRT vs. conventional radiotherapy (PARSPORT) (n=82) formed the basis of this non-randomized comparison. Patients in the PARSPORT trial received radiation alone (RT). Radiation dose for all patients was radiobiologically equivalent to at least 70Gy in 35 fractions. Concomitant chemotherapy was cisplatin (100 mg/m2) on days 1 and 29. G3 dysphagia was recorded prospectively. Dose volume histograms (DVH) were generated for the pharyngeal mucosa. The mean dose (converted to equivalent dose in 2Gy/fraction, MD2) was used as a univariate descriptor of the DVH, for the generation of the dose response curves. A logistic function of the form p=1/[1+(MD50/D)k] was fitted where, p is the probability of the incidence of toxicity, D is the mean dose, MD50 is the mean dose at which 50% of patients experience toxicity and k describes the increase in incidence with increasing dose. The dose response curves were fitted using non-linear logistic regression. Results: The mean MD2 to the pharyngeal mucosa were 56Gy and 55.8Gy respectively, in the CRT and RT groups. There was a statistically significant difference of 25% (95% CI: 10–38, p=0.002) in the incidence of G3 dysphagia between the CRT (68%) and RT (43%) groups. Fitting dose response curves to the clinical data yielded parameter values (95% CIs) of MD50=46 Gy (42–49), k=4.8 (2.3–7.2) for the CRT group and MD50= 58 Gy (55–61), k=3 (1.6-.45) for RT group. Dose response gradients for CRT and RT showed approximately 1.95% and 1.3% increase (respectively) in probability of G3 dysphagia resulting from an increase in mean dose of 1Gy between doses of 30Gy to 70Gy. Conclusions: Addition of concomitant chemotherapy increases the incidence of G3 dysphagia by 0.65% for every 1 Gy increase in radiation dose. The observed MD50 for G3 dysphagia is lower for RT alone (46 Gy vs. 58 Gy). No significant financial relationships to disclose.


Sign in / Sign up

Export Citation Format

Share Document